Clinical Course of Lung Cancer Patients with Subcutaneously Implanted Central Venous Access Device Ports from the Time of Receiving Chemotherapy to the Endpoint of Cancer — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Clinical Course of Lung Cancer Patients with Subcutaneously Implanted Central Venous Access Device Ports from the Time of Receiving Chemotherapy to the Endpoint of Cancer
Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Palliative Medicine Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Gastroenterological and Breast Surgery Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Gastroenterological and Breast Surgery Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Nursing Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Nursing Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Pharmacy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Palliative Medicine Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Departments of Gastroenterological and Breast Surgery Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
,
Tsumori Clinic, Osaka, Japan
1 Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
2 Departments of Palliative Medicine Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
3 Departments of Gastroenterological and Breast Surgery Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
4 Departments of Gastroenterological and Breast Surgery Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
5 Departments of Nursing Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
6 Departments of Nursing Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
7 Departments of Pharmacy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
8 Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
9 Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
10 Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
11 Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
12 Departments of Thoracic Malignancy Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
13 Departments of Palliative Medicine Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
14 Departments of Gastroenterological and Breast Surgery Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
Background: As the prognosis of lung cancer (LC) patients improves, subcutaneously implanted central venous access device ports (CV-ports) have frequently been used for continuing chemotherapy (CC) or palliative care (PC). In this study, we examined the clinical course of LC patients with subcutaneously implanted CV-ports from the time of receiving chemotherapy to the endpoint of cancer. Materials and Methods: We retrospectively reviewed the clinical data and treatment history of LC patients with subcutaneously implanted CV-ports between June 2008 and November 2013 using clinical records and a pharmacy database. Results: Of the 132 LC patients with subcutaneously implanted CV-ports, 79 (59.8%) had CV-ports for CC (the CC group) and 53 (40.2%) had CV-ports for PC (the PC group). After CV-port implantation, LC patients in the CC group received a median of two regimens with a median of 6 cycles. The median survival time of patients in the CC and PC groups was 457 and 44 days, respectively. In the CC group, the median survival time of small cell and non-small cell LC patients was 342 (95% confidence interval, 235 - 627) and 563 (95% confidence interval, 368 - 728) days, respectively. Nine patients (6.8%) had their CV-ports removed due to complications. Forty (30.3%) of the 132 enrolled patients were referred for at-home PC. The at-home death rate observed among these 40 patients was 30.0% ( N = 12). Conclusion: CV-ports may contribute to seamless oncological care.
KeywordsClinical CourseAt-Home Death RateImplanted Central Venous Access Device PortLung CancerSeamless Oncological Care
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. http://dx.doi.org/10.3322/caac.20107
Mitsudomi, T., Morita, S., Yatabe, Y., et al. (2012) Updated Overall Survival Results of WJTOG 3405, a Randomized Phase III Trial Comparing Gefitinib (G) with Cisplatin Plus Docetaxel (CD) as the First-Line Treatment for Patients with Non-Small Cell Lung Cancer Harboring Mutations of the Epidermal Growth Factor Receptor (EGFR). Journal of Clinical Oncology, 30, 7521.
Inoue, A., Kobayashi, K., Maemondo, M., et al. (2013) Updated Overall Survival Results from a Randomized Phase III Trial Comparing Gefitinib with Carboplatin-Paclitaxel for Chemo-Naive Non-Small Cell Lung Cancer with Sensitive EGFR Gene Mutations (NEJ002). Annals of Oncology, 24, 54-59. http://dx.doi.org/10.1093/annonc/mds214
Hirashima, T., Suzuki, H., Kobayashi, M., et al. (2012) Long-Term Chemotherapy May Prolong Survival in Advanced Non-Small-Cell Lung Cancer Among Responders to First-Line Chemotherapy. Medical Oncology, 29, 1629-1637. http://dx.doi.org/10.1007/s12032-011-0034-6
Hirashima, T., Suzuki, H., Okamoto, N., Morishita, N., Yamadori, T., Tamiya, M., Shiroyama, T., Kurata, K. and Kawase, I. (2014) Important Factors for Achieving Survival of Five Years or More in Non-Small Cell Lung Cancer Patients with Distant Metastasis. Oncology Letters, 8, 327-334. http://dx.doi.org/10.3892/ol.2014.2107
Suzuki, H., Hirashima, T., Kobayashi, M., et al. (2013) Impact of Pneumonia on Hyperactive Delirium in End-Stage Lung Cancer Patients. Support Care Cancer, 21, 281-285. http://dx.doi.org/10.1007/s00520-012-1522-8
Higashiguchi, M., Hirashima, T., Goya, S., et al. (2012) Predictors of Home Deaths in Patients with Terminal Lung Cancer: A Single Center Retrospective Study. AJRS, 1, 458-463.
Biffi, R., de Braud, F., Orsi, F., et al. (1998) Totally Implantable Central Venous Access Ports for Long-Term Chemotherapy. A Prospective Study Analyzing Complications and Costs of 333 Devices with a Minimum Follow-Up of 180 Days. Annals of Oncology, 9, 767-773. http://dx.doi.org/10.1023/A:1008392423469
Shiono, M., Takahashi, S., Kakudo, Y., et al. (2014) Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion. PLoS ONE, 9, e91335. http://dx.doi.org/10.1371/journal.pone.0091335
Sanjo, M., Miyashita, M., Morita, T., Hirai, K., Kawa, M., Akechi, T. and Uchitomi, Y. (2007) Preferences Regarding End-of-Life Cancer Care and Associations with Good-Death Concepts: A Population-Based Survey in Japan. Annals of Oncology, 18, 1539-1547. http://dx.doi.org/10.1093/annonc/mdm199
Ministry of Internal Affairs and Communications Bureau of Statistics (2011) e-Stat Portal Site of Official Statistics of Japan. http://e-stat.go.jp/SG1/estat/List.do?lid=000001108740.html
Kaplan, E.L. and Meier, P. (1958) Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association, 53, 457-481. http://dx.doi.org/10.1080/01621459.1958.10501452
Paz-Ares, L., de Marinis, F., Dediu, M., et al. (2012) Maintenance Therapy with Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care after Induction Therapy with Pemetrexed Plus Cisplatin for Advanced Non-Squamous Non-Small-Cell Lung Cancer (PARAMOUNT): A Double-Blind, Phase 3, Randomised Controlled Trial. The Lancet Oncology, 13, 247-255. http://dx.doi.org/10.1016/S1470-2045(12)70063-3
Sandler, A., Gray, R., Perry, M.C., et al. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumabfor Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 355, 2542-2550. http://dx.doi.org/10.1056/NEJMoa061884
Zhou, C., Wu, Y.L., Chen, G., et al. (2015) BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients with Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 19, 2197-2204. http://dx.doi.org/10.1200/JCO.2014.59.4424
Higashiguchi, M., Suzuki, H., Hirashima, T., et al. (2012) Long-Term Amrubicin Chemotherapy for Small-Cell Lung Cancer. Anticancer Research, 32, 1423-1427.
Murakami, H., Yamamoto, N., Shibata, T., et al. (2014) A Single-Arm Confirmatory Study of Amrubicin Therapy in Patients with Refractory Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer, 84, 67-72. http://dx.doi.org/10.1016/j.lungcan.2014.01.012
Kawaguchi, T., Ando, M., Asami, K., et al. (2014) Randomized Phase III Trial of Erlotinib versus Docetaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology, 18, 1902-1908. http://dx.doi.org/10.1200/JCO.2013.52.4694
Hohl Moinat, C., Périard, D., Grueber, A., Hayoz, D., Magnin, J.-L., André, P., Kung, M. and Betticher, D.C. (2014) Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients. Journal of Oncology, 2014, Article ID: 743181. http://dx.doi.org/10.1155/2014/743181
Wright, A.A., Keating, N.L., Balboni, T.A., et al. (2010) Place of Death: Correlations with Quality of Life of Patients with Cancer and Predictors of Bereaved Caregivers' Mental Health. Journal of Clinical Oncology, 28, 4457-4464. http://dx.doi.org/10.1200/JCO.2009.26.3863
Fukui, S., Fujita, J., Tsujimura, M., Sumikawa, Y. and Hayashi, Y. (2011) Predictors of Home Death of Home Palliative Cancer Care Patients: A Cross-Sectional Nationwide Survey. International Journal of Nursing Studies, 48, 1393-1400. http://dx.doi.org/10.1016/j.ijnurstu.2011.05.001
Cohen, J., Houttekier, D., Onwuteaka-Philipsen, B., et al. (2010) Which Patients with Cancer Die at Home? A Study of Six European Countries Using Death Certificate Data. Journal of Clinical Oncology, 28, 2267-2273. http://dx.doi.org/10.1200/JCO.2009.23.2850